<DOC>
	<DOCNO>NCT02452242</DOCNO>
	<brief_summary>ABX464 first class show efficacy anti-HIV therapy . The present study intend assess safety , tolerability , pharmacokinetic parameter evaluate effect viral load repeat oral administration ABX464 patient infected HIV , previously treat HIV . Two type design intend protocol : dosing every 3 day dose every day . The goal determine best dose regimen reduce viral load minimize adverse event .</brief_summary>
	<brief_title>Safety , PK PD Study ABX464 Untreated HIV Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>1 . Males female , 18 65 year age 2 . Patients infected HIV1 HIV2 3 . BMI 17 29 kg/m² . 4 . CD4 cell count ≥ 350 /mm3 HIV RNA level 5,000500,000 copies/mL . 5 . Clinical laboratory test ( hematology , blood chemistry , urinalysis ) must within normal limit , clinically acceptable sponsor principal investigator consistent underlie HIV infection . 6 . Urine drug screen drug high potential abuse ( cocaine , opiates , amphetamine barbiturate ) alcohol breath test must negative . 7 . Females must non lactate either nonchildbearing potential ( ie sterilize via hysterectomy bilateral tubal ligation least one year postmenopausal ) child bear potential , must practice effective double barrier contraceptive method least two week prior Day 1 3 month last dose study medication . 8 . Males must practice effective barrier method contraception Day 1 3 month day last dose study medication . 9 . Patients must willing give write informed consent prior study enrollment able adhere restriction examination schedule . 10 . Physical examination ECG must within normal limit . 11 . Never take antiretroviral agent except brief time , reason , patient decide continue therapy ( i.e . Toxicity , personal decision . None past 30180 day . 1 . Individuals history significant medical disorder require physician 's care . 2 . Individuals history clinically significant local systemic infectious disease ( HIV1 HIV2 infection ) within four week prior drug administration . 3 . Individuals clinically significant laboratory abnormality define grade 2 3 Common Terminology Criteria Adverse Events ( CTCAE ) , version 4.0 . 4 . Individuals positive hepatitis B virus and/or hepatitis C virus 5 . Any individual comply requirement use drug ( include prescription , nonprescription , herbal , mineral supplement ) paracetamol least two week prior study alcohol within 48 hour prior drug administration entire study period . The use concomitant medication treat AE study consider protocol violation . 6 . Individuals participate clinical trial investigational drug within 90 day prior start study 7 . Individuals smoke ten cigarette equivalent tobacco use per day . 8 . Individuals forfeiture freedom administrative legal obligation guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>